Business Context and Reporting Period
This Form 8-K was filed by Tivic Health Systems, Inc. (trading symbol: TIVC) on June 18, 2025. The report details the entry into a material definitive agreement regarding the company's intellectual property portfolio.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The only specific financial figures disclosed relate to the amended payment terms of a license agreement:
- Payment Cap: Subsequent payments due to Statera Biopharma, Inc. under the new agreement are capped at an aggregate of up to $5.6 million.
- Payment Method: The company may pay royalties in either cash or company securities at its discretion.
- Payment Recipient: Payments up to the $5.6 million cap are to be made directly to Avenue Capital on behalf of Statera.
Material Changes Versus Prior Period
The company entered into an Amended and Restated Exclusive License Agreement with Statera Biopharma, Inc., superseding the Original License Agreement signed on February 11, 2025. The material changes include:
- Payment Flexibility: Royalties may now be paid in cash or Tivic Health Systems securities, whereas the original terms did not explicitly specify this discretion.
- Payment Routing: All subsequent payments (up to the $5.6 million aggregate limit) are now directed to Avenue Capital rather than directly to Statera.
- Scope: The agreement continues to cover the exclusive worldwide license for the TLR5 agonist program (Entolimod) for Acute Radiation Syndrome and options for additional indications (Lymphocyte Exhaustion, Immunosenescence, Neutropenia, Vaccine Adjuvant) and the Entolasta program.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the terms of the new agreement are substantially similar to the original, with the exceptions noted above. The company directs investors to the Prior 8-K (filed February 12, 2025) for a full summary of the original material terms.
Risks and Contingencies: The filing notes that certain confidential portions of the agreement have been omitted from the public exhibit. The company agrees to furnish unredacted copies to the SEC upon request. No specific forward-looking guidance or new risk factors were introduced in this specific report beyond the standard incorporation of the agreement text.
Important Facts for Investor Verification
- Verify the specific terms of the Original License Agreement filed on February 12, 2025, to understand the baseline obligations before the amendment.
- Confirm the identity and role of Avenue Capital in relation to Statera Biopharma to understand the payment structure.
- Review the full text of Exhibit 10.1 (Amended and Restated Exclusive License Agreement) for any omitted confidential terms that may impact valuation or obligations.
- Monitor future filings for the actual utilization of the securities payment option, which could lead to dilution of existing shareholders.